Ketoprofen as an Add-on Treatment to Sertraline for Drug-Naïve Major Depressed Patients: Normalization of Plasma Levels of Indoleamine-2,3-Dioxygenase in Association with Pro-Inflammatory and Immune Regulatory Cytokines

Prof. Dr. Hussein Kadhem Al-Hakeim (1)
Dr. Ahmed Jasim Twayej (2)
Assist. Prof. Dr. Arafat Hussein Al-Dujaili (3)
Prof. Dr. Michael Maes, M.D., Ph.D. (4-6)

(1) Department of Chemistry, College of Science, Kufa University-Iraq. E-mail: headm2010@yahoo.com.
(2) Pathological Analysis Department, College of Health and Medical, Al-Kafeel University, Najaf, Iraq. E-mail: AJM.Chem@yahoo.com.
(3) Senior Clinical Psychiatrist, Faculty of Medicine, Kufa University. E-mail: arafat.aldujaili@uokufa.edu.iq.
(4) Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
(5) Department of Psychiatry, Medical University Plovdiv, Plovdiv, Bulgaria.
(6) IMPACT Research Center, Deakin University, Geelong, Australia.

Abstract

Major Depression Disorder (MDD) is accompanied by an immune response characterized by increased levels of pro-inflammatory and immune-regulatory cytokines and cytokine-induced stimulation of indoleamine-2,3-dioxygenase (IDO). There is also some evidence that anti-inflammatory drugs may have a clinical efficacy in MDD.

The aim of this study is to examine the clinical effects of an eight-week combinatorial treatment of ketoprofen (a nonsteroidal anti-inflammatory drug) combined or not with sertraline,
on serum levels of IDO, interferon (IFN)-γ, interleukin (IL)-4 and transforming growth factor (TGF)-β1 in association with changes in the Beck-Depression Inventory-II (BDI-II). The study included 140 MDD patients and 40 normal controls.

The pre-treatment serum levels of IDO, IFN-γ, TGF-β1 and IL-4 were significantly higher in MDD patients compared with the control group. Treatment with sertraline with or without ketoprofen significantly reduced the increased baseline production of all 4 biomarkers to levels which were similar as those of normal controls. Ketoprofen add-on had a significantly greater effect on IDO and BDI-II as compared with placebo. The reductions in IDO, IL-4 and TGF-β1 during treatment were significantly associated with those in the BDI-II.

In conclusion, the clinical efficacy of both sertraline + ketoprofen may be ascribed at least in part to attenuated IDO levels and immune-inflammatory responses in MDD. Moreover, add-on treatment with ketoprofen may augment the efficacy of sertraline by attenuating IDO. However, these treatments may also significantly reduce the more beneficial properties of T helper-2 and T regulatory (Treg) immune subsets. Future research should develop immune treatments that target the immune-inflammatory response in MDD, while enhancing the compensatory immune-regulatory system (CIRS).

Keywords: Major depressive disorder (MDD), ketoprofen, TGF-β1, INF-γ, IDO, immune, inflammation
Introduction

There is now evidence that Major Depressive Disorder (MDD) is an immune-inflammatory disorder accompanied by higher levels of pro-inflammatory cytokines, acute phase proteins and complement factors (Maes, 1993; Al-Hakeim, 2008; Maes, 2011a; Köhler et al., 2017). A recent review shows that MDD is accompanied by activation of M1 macrophages (with increased production of interleukin (IL)-1β and IL-6, T helper (Th)1 cells (with increased production of interferon (IFN)-γ), Th2 activation (with increased production of IL-4), and a T regulatory (Treg) response (with increased production of IL-10) (Maes and Carvalho, 2018). This is important as IL-4 and IL-10 have immune regulatory effects attenuating the activation of Th1 and macrophagic M1 cells. This shows that MDD is accompanied by increased production and secretion of mediators that have immune regulatory or anti-inflammatory effects and that serve an adaptive purpose down-regulating the primary immune-inflammatory response. This new concept was called the “compensatory immune regulatory system” (CIRS) (Maes and Carvalho, 2018).

Elevated production of IFN-γ and M1 macrophagic cytokines may lead to activation of peripheral and brain levels of indoleamine-2,3-dioxygenase (IDO) (Maes et al., 1994; 2011b). Cytokine-induced activation of this enzyme leads to increased degradation of L-tryptophan (TRP) resulting in decreased serotonin synthesis and concomitant increases in TRP catabolites (TRYCATs) (Maes et al., 1994; 2011b). Therefore, activation of IDO may play a role in depression by taking TRP away from serotonin synthesis and increasing the production of neurotoxic and excitotoxic TRYCATS (Maes et al., 2002; Chaves Filho et al., 2011; Maes et al., 2011b).
Studies indicate that in a considerable part of patients with MDD (30-40%), symptoms may be resistant to pharmacological treatment with antidepressants (Hernandez et al., 2013). Most antidepressant drugs are still designed to increase monoamine transmission either by inhibiting neuronal reuptake, e.g., by using TCAs, selective serotonin reuptake inhibitors (SSRIs), and serotonin noradrenaline reuptake inhibitors, or by inhibiting monoamine degradation, e.g., using monoamine oxidase inhibitors (David & Gardier 2016). There is now also evidence that antidepressants have anti-inflammatory as well as immune-regulatory effects by attenuating the production of pro-inflammatory cytokines (IFN-γ and M1 macrophagic) and increasing that of negative immune-regulatory cytokines such as IL-10 and transforming growth factor (TGF)-β1, another Treg cytokine (Xia et al., 1996; Maes et al., 1999; Lee et al., 2006; Blatteau et al., 2015). SSRIs including sertraline may change the proinflammatory / anti-inflammatory cytokine balance via increasing production of IL-10 and TGF-β1, which have multiple suppressive actions on T cells, macrophages, and other cells (Maes et al., 1999; Lee et al. 2006). Nevertheless, other studies showed that sertraline not only suppresses inflammatory cytokines, including IL-2, IL-6, IL-17 and IFN-γ, but also immune regulatory cytokines, including IL-4 and IL-10 (Brunoni et al., 2014). Sertraline may also inhibit microglial activation through inhibition of IFN-γ-induced elevation of intracellular calcium ions (Horikawa et al., 2010).

Depression is not only accompanied by increased levels of pro-inflammatory cytokines, but also by increased cyclooxygenase-2 (COX-2) expression and prostaglandin production (Song et al., 1998; Galecki et al., 2012; Maes et al., 2012a). Consequently, COX-2 inhibitors are also of interest as adjunctive treatments in depression (Faridhosseini et al., 2014). Similarly, agents with negative immune regulatory effects have potential antidepressant properties, including omega-3
polyunsaturated fatty acids, infliximab, curcumin, aspirin, statins and N-acetylcysteine (Maes et al., 2012b; Fernandes et al., 2016). Several clinical trials showed that adding non-steroidal anti-inflammatory drugs (NSAIDs) such as COX inhibitors to SSRIs may help to reduce the severity of depression (Müller et al., 2013). However, another large-scale study evaluating the efficacy of NSAIDs as mono-therapy for late-life depression in ~2500 elderly adults showed no significant effect in reducing depressive symptoms compared with placebo (Fields et al., 2012). A recent meta-analysis pooling results from all available randomized trials testing NSAIDs and cytokine inhibitors as antidepressants showed that anti-inflammatory treatments reduced depressive symptoms compared with placebo (Köhler et al., 2014). Nevertheless, there are no data whether treatments with sertraline with or without ketoprofen (a non-specific COX inhibitor that has anti-inflammatory properties by inhibiting COX-2 thereby decreasing the production of proinflammatory prostaglandin precursors) significantly decreases IDO and the IFN-γ / IL-4 + TGF-β1 ratio in association with clinical recovery.

Hence, the aim of the present work was to study whether the efficacy of the anti-inflammatory drug ketoprofen as an adjuvant therapy to traditional antidepressants (sertraline) is associated with reductions in IDO, IFN-γ levels and an increased IFN-γ / IL-4 + TGF-β1 ratio in MDD patients.

Materials and Methods

Participants

A total of one hundred and forty MDD patients and 40 normal controls participated in the present study. Patients were recruited at the Psychiatry Unit, Al-Hakeem General Hospital in Najaf Governorate-Iraq and at a private psychiatric clinic run by an assistant professor in
psychiatric medicine during the period from November 2016-August 2017. The patients were
diagnosed by psychiatrists according to a semi-structured psychiatric interview schedule for the
diagnosis of MDD based on the ICD-10 (10th revision of the International Statistical
Classification of Diseases and Related Health Problems). Forty apparently healthy subjects were
selected as control group. Their sex and age were comparable to that of patients. These subjects
were free from psychiatric (axis-1) and somatic diseases. Patients and controls were evaluated
through a complete medical history to exclude any systemic diseases that may affect the
biomarkers, including diabetes mellitus, liver and kidney diseases, (auto)immune disorders and
neurological disorders, including multiple sclerosis, stroke and Parkinson’s disorder. Exclusion
criteria for participants were any systemic or inflammatory disease. C-reactive protein (CRP)
was not higher than 6 mg/L, excluding subjects with overt inflammation.

The present study is part of a prospective, 2-months, randomized double-blind study of
parallel groups of patients with MDD with or without ketoprofen administration in addition to
sertraline. In this study, we included 44 of the 140 MDD patients, namely those who had their
blood sampled for biomarker assays at baseline and after the treatment. All biomarker assays
were complete in these 44 subjects and there were no missing values in the BDI-II scores.
Among the follow up group, sixteen patients received traditional treatment (sertraline, orally 50
mg once daily) and twenty eight patients were treated with anti-inflammatory drug (ketoprofen,
100 mg orally once daily) as adjuvant to sertraline for treatment of MDD. Patients were
instructed to take one capsule daily after breakfast. The coloured empty capsules (Caps &
Chemicals, India) were filled either with sertraline (Actavis, Italy) alone, for the placebo group or
filled with sertraline + ketoprofen (Menarini Int., Italy) for drug adjuvant group. The laboratory
analysts were blinded to the treatment modalities. The protocol was approved by the IRB of the
University of Kufa (#221, June 2016). The patients or their close first-degree relatives provided informed consent in accordance with the procedures outlined by the current IRB. The study is recorded in the NIH US Library of Medicine, ClinicalTrials.gov Identifier: NCT03514810.

Measurements

The total score on the Beck-Depression Inventory (BDI-II) (Beck et al., 1996) was used to rate severity of illness. The BDI-II score was obtained in all MDD patients at baseline and was also rated two months after starting treatment in the 44 patients who were included in the biomarker treatment study. Five milliliters of venous blood samples was drawn by utilizing disposable needles and plastic syringes. The samples were transferred into clean plain tubes. Haemolyzed samples were discarded. The blood was left at room temperature for 10 minutes for clotting, centrifuged 3000 rpm for 5 minutes, and then serum was separated and transported into three new Eppindroff® tubes until assay. Serum IDO, IL-4, INFγ, and TGF-β1 were measured by using ELISA kits supplied by MYBioSource® Inc., USA. All kits were based on a sandwich technique and showed an inter-assay CV less than 12%. Briefly, serum containing analyte was added to the wells pre-coated with monoclonal antibody of the analyte. After incubation, a biotin-conjugated anti-human analyte antibody was added to bind the human analyte. After washing, streptavidin-HRP was added to bind to the biotin-conjugated anti-human analyte antibody and after incubation, the substrate solution was added followed by color development proportionally to the amount of human analyte. The reaction was terminated by addition of acidic stop solution and absorbance was measured at 450 nm and transformed into concentration by using standard curves.
Statistical Analysis

We used analysis of contingency tables (χ² test) to check associations between categorical variables and analysis of variance (ANOVAs) to check differences in continuous variables between groups. Protected pairwise post-hoc analyses were employed to examine the differences between group means. Multivariate general linear model (GLM) analysis was used to examine the effects of diagnosis (MDD versus controls) on the different biomarkers, which were entered as dependent variables. The primary outcome analysis is a linear mixed model (LMM) repeated measures analysis to assessresponsivity of biomarkers to treatment with sertraline with or without ketoprofen from baseline to endpoint. The pre-specified LMM analyses included fixed categorical effects of ketoprofen treatment, time and time-by-treatment interactions; while sex and age were entered as random effects. Baseline data (demographic and clinical data) were assessed for balance between the ketoprofen and placebo treatment groups using analyses of contingency tables (χ² test) and ANOVAs. Power analysis to detect the add-on effects of ketoprofen on BDI-II scores, using a 2-tailed test at α=0.05 and assuming an effect size of 0.13 with power of 0.80, shows that the required sample size is around 142 participants. However, only 44 patients were included in the current biomarker study because the grant support was limited and, consequently, the present biomarker study shows a post-hoc achieved power of 0.658. Tests were 2-tailed and a p-value of 0.05 was used for statistical significance. All statistical analyses were performed using IBM SPSS windows version 25. Statistical analyses were conducted in accordance with the International Conference on Harmonisation E9 statistical principles (November 2005). We computed two z unit weighted composite scores (Maes and Carvalho, 2018). A first one reflected Th2 + Treg functions and was computed as z
transformation of \( \ln IL-4 (z\ ln IL-4) + z\ ln TGF-\beta1 \). The second composite score reflected the Th1 / Th2 + Treg ratio and was computed as \( z\ ln IFN-\gamma - z(z\ ln IL-4 + z\ ln TGF-\beta1) \).

Results

**Socio-demographic data**

Table 1 shows the socio-demographic, clinical and biomarker data of the participants in this study. In this table we examine differences in these variables between major depressed patients at baseline and healthy controls and between depressed patients at endpoint and controls. The data were not adjusted for p-correction because the results of this Table (and the intercorrelation matrix between the variables) were used to determine the variables to be used as background (extraneous) variables in the ultimate multivariate analyses with the biomarkers as dependent variables. Nevertheless, this table shows that there were no significant differences in age, sex, employment status, rural/urban ratio, and BMI between the study groups. There were more smoking and not-married (single) subjects in the depressed group as compared with controls. The levels of IDO, IFN-\( \gamma \), IL-4, TGF-\( \beta \) and the index Th2 + Treg were significantly different between major depressed patients at baseline and normal controls. There were no significant differences in the Th1 / Th2+Treg ratio between major depressed patients at baseline and healthy controls. There were no significant differences in levels of IDO, IFN-\( \gamma \), IL-4, TGF-\( \beta \) and the Th2 + Treg and Th1 / Th2 + Treg indices between MDD post-treatment and control values.

After p-correction there were significant associations between IDO and levels of IL-4 (\( r=0.190, p=0.028 \)) and the Th2 + Treg index (\( r=0.222, p=0.015 \)), but not IFN-\( \gamma \) (\( r=0.130, p=0.103 \)) or the Th1 / Th2 + Treg index (\( r=-0.012, p=0.873 \)) (all \( n=180 \), performed on all
controls and depressed patients at baseline). After p-correction, we found that IFN-γ was significantly associated with IL-4 ($r=0.455$, $p<0.001$), TGF-β1 ($r=0.309$, $p<0.001$) and Th2 + Treg index ($r=0.488$, $p<0.001$) (all $n=180$). There were also significant association between IL-4 and TGF-β1 ($r=0.282$, $p<0.01$). In patients there were no significant associations between the baseline immune biomarkers and pre-treatment BDI-II scores.

*Differences in the biomarkers between major depressed patients at baseline and controls*

*Table 2* shows the outcome of a multivariate GLM analysis with the 6 biomarker values as dependent variables and diagnosis as primary outcome variable, while adjusting for sex, TUD, age and BMI. We found a highly significant association between the biomarkers (at baseline) and diagnosis. Tests for between-subjects effects showed that IDO, the three cytokines / chemokines and the Th2 + Treg score, but not the Th1 /Th2 + Treg score, were significantly associated with diagnosis with a particularly strong effect on IL-4 (partial $\eta^2=0.203$), the Th2 + Treg index (partial $\eta^2=0.185$) and IFN-γ (partial $\eta^2=0.122$). There were no significant associations between diagnosis and the Th1 / Th2 + Treg score.

*Table 2* also shows that there were no significant effects of age, sex, TUD and BMI on the 6 immune biomarkers. In addition, multivariate GLM analysis showed that there were no significant effects of employment status ($F=0.07$, $df=4/213$, $p=0.990$), the rural / urban ratio ($F=0.21$, $df=4/213$, $p=0.932$) and marital status ($F=2.21$, $df=4/213$, $p=0.069$).

*Table 3* shows the model-generated estimated marginal mean (in z transformations) values of the 6 biomarkers obtained by the GLM analysis shown in Table 2. The levels of IDO, IFN-γ, IL-4, TGF-β and the Th2 + Treg index were all significantly greater in MDD than in healthy controls.
**Effects of treatments on the BDI-II score and immune biomarkers.**

Table 4 shows the baseline characteristics of both treatment groups. We found no significant differences in any of the demographic (age, sex, marital and employment status, urban/rural ratio) and clinical (baseline BDI, BMI and TUD) data between both treatment groups. In addition, there were no significant differences in any of the baseline biomarker levels between both treatment groups. There were also no significant differences in age, sex ratio, smokers, BDI-II score, IDO, IFN-γ, IL-10 and TGF-β1 between the 44 MDD patients who had biomarker assays after treatment and the remaining 96 MDD patients.

Table 5 shows the results of LMM analysis, namely the effects of treatment on the BDI and the 6 immune biomarkers. Shown are the effects of time and treatment X time, as well as the pre- and post-treatment mean (SE) values. We found that treatment (time) significantly reduced the BDI-II score. There was also a significant time X treatment effect showing that the effects of sertraline + ketoprofen (pre-treatment and post-treatment means (SE): 48.8 ±1.9 and 13.4 ±1.3, respectively) was significantly greater than those of sertraline + placebo (49.9 ±2.5 and 19.7 ±1.7, respectively). There were no significant effects of any on the background variables on these effects (sex, age, MBI, TUD, marital and employment status, and rural/urban ratio). There were significant effects of treatment (time) on IDO, all 4 cytokines and the Th2 +Treg index, but not the Th1 / Th2 + Treg index. We also found a significant treatment X time interaction on IDO with a significantly greater effect of sertraline + ketoprofen (pre-treatment and post-treatment means (SE): 48.7 ±5.2 U/L and 33.0 ±4.3 U/L, respectively) as compared with sertraline + placebo (41.0 ±5.8 U/L and 35.4 ±4.3 U/L, respectively).
Using LMM analysis we also examined the associations between changes in the BDI-II and biomarker levels. LMM analysis (adjusted for treatment and all extraneous variables shown in table 1) showed significant positive associations between BDI-II and IDO (F=18.14, df=1/55, p<0.001), IFN-γ (F=12.54, df=1/71, p=0.001), IL-4 (F=48.09, df=1/82, p<0.001), TGF-β (F=22.24, df=1/60, p<0.001), and the Th2 + Treg index (F=55.62, df=1/69, p<0.001), but not the Th1 / Th2 + Treg index (F=3.87, df=1/67, p=0.053). Entering all biomarkers as explanatory variables in a LMM analysis (repeated measurements) with BDI-II as dependent variable showed that the BDI-II score from baseline to endpoint was significantly associated with IDO (F=20.38, df=1/75, p<0.001), IL-4 (F=13.01, df=1/74, p=0.001) and TGF-β (F=6.97, df=1/56, p=0.011). There were no significant associations (even without p-correction) between any of the baseline biomarker data and the post-treatment BDI-II values or the residualized post-treatment BDI values (after regression on the baseline BDI-II values). LMM analysis (adjusted for treatment and all extraneous variables shown in table 1) showed significant positive associations between IDO and IL-4 (F=9.50, df=1/66, p=0.003), but not any of the other cytokines.

Discussion

1-Comparison of the baseline biomarkers between MDD patients and controls

The first major finding of this study is that IDO and the three cytokines measured here were significantly higher in MDD patients than in normal controls. A significant increase in IDO levels in MDD patients was previously reported in some papers (Zoga et al., 2014; Kopschina Feltes et al., 2017). Not all authors, however, could find increased IDO activity as estimated by the kynurenine / TRP ratio in MDD (Maes et al., 2011c). Higher levels of serum IDO and inflammatory mediators (TNF-α, IFN-γ and CRP) and lower levels of serotonin were found at
baseline in MDD patients as compared with healthy controls (Zoga et al., 2014). Increased activity of IDO may result in depletion of serotonin and an increase in neurotoxic and excitotoxic TRYCATs, including kynurenine and quinolinic acid (Kim et al., 2012; Quak et al., 2014, Badawy et al 2017). Increased levels of quinolinic acid, for example, may impair the reuptake of glutamate into synaptic vesicles, which leads to the production of reactive oxygen and nitrogen species and up-regulates proinflammatory chemokines and cytokines in astrocytes (Bay-Richter et al., 2015, Mechawar & Savitz 2016). The significant increases in serum IFN-γ, IDO, IL-4, TGF-β as well as the Th2 + Treg index, indicate activation of immune pathways coupled with CIRS activation. The latter should be viewed as an adaptive process which attempts to compensate for the activated immune-inflammatory pathways (Maes and Carvalho, 2018).

Increased levels of IL-4 and TGF-β1 in MDD patients may occur secondarily to the primary immune-response comprising Th1 and M1 macrophagic activation (Maes and Carvalho, 2018).

There are now many meta-analysis studies showing that depression is accompanied by an immune-inflammatory response with increased levels of pro-inflammatory and immune-regulatory CIRS cytokines (Strawbridge et al., 2015; Köhler et al., 2017). Increased IFN-γ levels in MDD patients have been reported previously (Maes et al., 1994; Dahl et al., 2014; Al-Hakeim et al., 2018b). Previous research reported increased IL-4 levels in MDD patients as compared with controls (Pavón et al., 2006), while others were unable to find such differences (Köhler et al., 2017). Although increased IL-4 may initially constitute a protective response (by regulating M1 and Th1 activation), this Th2 cytokine also exhibits more detrimental effects. For example, in vitro studies show that IL-4 may diminish IDO expression in dendritic cells (Tu et al., 2017) (thereby decreasing the protective CIRS effects of the TRYCAT pathway), reduce dendritic cell expression of IL-10 thereby promoting a Th1 phenotype and inhibiting Treg cell differentiation.
(Yao et al., 2005; Tu et al., 2017). This may explain that IL-4 is involved in certain types of inflammatory diseases by orchestrating the functional phenotype of dendritic cells (Tu et al., 2017).

Finally, while the current study reports increased TGF-β1 levels in MDD, a previous meta-analysis did not find any changes in this cytokine (Köhler et al., 2017). Earlier research suggested that TGF-β1 may play a role in the pathophysiology of depression in patients who have an imbalance in Th1 and Th2 cytokines (Myint et al., 2005). Interestingly, we found that the ratio of Th1 / Th2 + Treg (computed as a z unit weighted composite score) was not significantly increased in MDD as compared with controls, while all three cytokines were increased in the acute phase of depression. This shows that the acute phase of depression is accompanied by an immune response with an interrelated activation of Th1, Th2 and Treg phenotypes and that there is no predominance of one of these phenotypes. This contrasts for example the findings in first episode psychosis, which is characterized by a significant predominance of M1 and Th1 versus Th2 and Treg phenotypes (Nunes Noto et al., 2018). Unfortunately, there are no other results on the M1 + Th1 / Th2 + Treg ratio in MDD patients.

2-Association between baseline IDO and cytokine levels

IFN-γ is the most important stimulus of IDO1 activity and thus increased IFN-γ levels in MDD may in theory explain IDO activation (Maes et al., 1994; Bonnacorso et al., 2002; Connor et al., 2008). This may have dire consequences because overproduction of pro-inflammatory cytokines, such as IFN-γ, can indirectly stimulate glutamatergic signaling by increasing IDO activity (Lichtblau et al., 2013; Mechawar & Savitz 2016). Nevertheless, in contrast to our a priori hypothesis, no significant correlation could be found between IDO levels and IFN-γ and
the Th1 / Th2 + Treg ratio, while there was an unexpected positive association between baseline IDO and IL-4 levels. These findings may be explained by the use of ELISA methods which are less sensitive to measure IFN-γ in the lower secretion range. Phrased differently, IL-4 is probably a better, more sensitive indicant of the immune response than IFN-γ. Moreover, IDO is not only activated by IFN-γ, but also IL-1β, IL-6, and TNF-α may increase IDO expression in both central and peripheral immune-competent cells (Connor et al., 2008; Maes et al., 2011c). As such, activated peripheral immune cells and microglia produce M1 and Th1 cytokines that may contribute to neuroprogression by activating IDO enzyme activity (Leonard and Maes, 2012; Kopschina Feltes et al., 2017).

3- Effects of antidepressive treatments on the biomarkers.

The second major finding of this study is that antidepressants significantly reduced IDO, IFN-γ, TGF-β1 and IL-4 concentrations to levels which were in the range of the values observed in our normal controls. According to Beck’s criteria (Beck 1996), most patients in our study showed at baseline a severe depression (score between 29 and 63), while after treatment the BDI-II scores were significantly reduced to values reflecting minimal depression (46.15%), mild depression (30.77%) and moderate depression (23.08%). There is now evidence that antidepressant treatments reduce the BDI-II score, which is therefore an adequate outcome measurement in clinical trials (Kolouri et al., 2016; Zamanian et al., 2017).

Our results that treatment with antidepressants significantly reduces IDO levels extent those of previous authors. Myint et al. (2007) reported a reduction in IDO levels during antidepressant treatment, which resulted from changes in inflammatory mediators modulated by
antidepressant treatment. Effective treatment with antidepressants decreased IDO levels and these effects were positively associated with clinical improvement (Zoga et al., 2014).

Already in the 1990ties it was shown that antidepressants have in vitro immune regulatory effects by lowering the production of pro-inflammatory M1 and Th1 cytokines (Xia et al., 1996; Maes et al., 1999). A 12-week treatment with antidepressants decreased IFN-γ levels to concentrations measured in healthy subjects (Dahl et al., 2014). In contrast to our findings, Lee et al. (2006) found that plasma TGF-β1 levels were significantly increased after 8-week treatment with sertraline. Treatment with antidepressants and mood stabilizers also attenuates the acute phase response in MDD, indicating that these drugs have immune regulatory effects in vivo (Maes et al., 1997). A recent meta-analysis showed that treatment with antidepressants decreases IL-6 and TNF-α indicating anti-inflammatory effects of antidepressants (Köhler et al., 2018). Sutcigil & Taler (2007) reported that patients with MDD have an imbalance between pro- and anti-inflammatory cytokines that can be normalized following antidepressant treatment.

Importantly, we found that the normalization of the four immune biomarkers was associated with clinical improvement as established by significantly reduced BDI-II levels after treatment. Thus, the current study shows a significant association between decrements in IDO and Th1, Th2 and Treg responses and clinical efficacy to antidepressants with or without ketoprofen. In contrast, the meta-analysis study by Köhler et al. (2018) could not find a significant association between antidepressant-induced reductions in cytokine levels and the clinical efficacy to antidepressants.

Therefore, it could be suggested that the normalization of the more detrimental components of the immune response may, in theory, be associated with the clinical efficacy of antidepressants. More specifically, normalization of IFN-γ and IDO may be associated with a
lowered synthesis of neurotoxic and excitotoxic TRYCATs and thus play a role in clinical improvement or remission. For example, the drug 1-methyltryptophan can inhibit IDO and has been successful in reducing depressive behaviors following inflammatory challenges in animal models (O’Connor et al., 2009). Clinical trials using 1-methyltryptophan as a putative anticancer agent have commenced in humans, although there is some debate as to whether this compound inhibits human IDO in vivo (Lob et al., 2008). However, IDO production may have immunosuppressive actions (Maes et al., 2007; Lob et al., 2008) because many TRYCATs have immune regulatory effects (Maes and Carvalho, 2018). In fact, the TRYCAT pathways is part of the CIRS and, therefore, suppression of IDO could deteriorate the primary immune response. Secondly, the reductions in IL-4 following our treatments may attenuate the above-mentioned more detrimental effects of IL-4, but is of course also accompanied by lowered immune regulation. Moreover, TGF-β1 has strong negative regulatory effects (Maes and Carvalho, 2018) although it also has some pro-inflammatory effects including effects on Th17 and Th1 cytokines (Han et al., 2012). Therefore, it remains unknown whether the significant correlations between clinical and immune responses as found in the current study indicate causal associations, and if so, which molecules may explain this association (IDO, IFN-γ, IL-4 and TGF-β1, alone or together). The most parsimonious explanation at this stage is that during antidepressant treatment the primary immune response is suppressed and that this is accompanied by a clinical improvement.

4-Add-on effects of ketoprofen

The third major finding of this study is that ketoprofen was significantly more efficacious in reducing IDO and the BDI-II score than placebo, although ketoprofen had no additional effects suppressing cytokine levels. Nevertheless, the significant effect of ketoprofen on IDO
disappeared after p-correction for multiple testing, while neither sertraline nor add-on treatment with ketoprofen altered the Th1 / Th2 + Treg ratio. Moreover, it should be underscored that the clinical effect of ketoprofen is not highly relevant; thus, sertraline alone reduced the BDI-II score from 49.9 at baseline to 19.7 post-treatment, whereas add-treatment with ketoprofen + sertraline reduced the BDI-II score from 48.8 to 13.4. A double blind, randomized clinical trial reported an advantage of reboxetine and the COX-2 inhibitor celecoxib over reboxetine and placebo (Müller et al., 2006). As reviewed in the introduction, there is now some evidence that celecoxib, a COX-2 inhibitor and different anti-inflammatory and anti-oxidative compounds may augment the clinical efficacy of antidepressants (Faridhosseini et al., 2014, Maes et al., 2012). Taking all those results and explanations into consideration, ketoprofen did not fulfill the requirements of a good antidepressant drug that should specifically target M1 and Th1, while increasing Th2 and especially Treg functions (Maes et al., 2012a). Moreover, COX-2 inhibitors, and especially their longer term use, may induce many side effects which in fact could aggravate the pathophysiology of depression (Maes et al., 2012b). These include increased Th1 activation, neuroinflammation, oxidative stress, gut permeability and damage to mitochondria and lowered levels of key antioxidants. Some previous studies reported increased benefit of anti-inflammatory drugs as adjuvant drugs in MDD patients especially those with increased baseline proinflammatory activity (Kohler et al., 2014; Krause et al., 2017). Nevertheless, the latter studies measured only responses of pro-inflammatory mediators to treatment and not Treg functions (Krause et al., 2017; Al-Hakeim et al 2018).

Limitation of the study
It would have been more interesting if we had included different M1 macrophagic cytokines, Th1 cytokines including IL-12 and IL-2, Th2 cytokines including IL-5 and especially the Treg cytokine IL-10. This would allow us to compute more comprehensive immune activation / CIRS ratios. Moreover, the size of the study sample did not achieve adequate power (0.658) to detect effects of add-on treatment with ketoprofen, although the effects of treatment on the measurements were well powered in a post-hoc power analysis (around 0.95).

**Conclusions**

The acute phase of depression is characterized by an interrelated response in Th1, Th2 and Treg phenotypes and increased IDO levels, while antidepressant treatment with sertraline normalized all these different phenotypes as well as IDO in association with clinical improvement. Treatment with sertraline with or without ketoprofen significantly reduced the BDI-II score, while ketoprofen add-on had a significantly greater effect on the BDI-II score than placebo. The clinical efficacy of sertraline and sertraline + ketoprofen may be ascribed to a reduction of the immune response in MDD. However, this treatment may also significantly reduce the more beneficial properties of Th2 and Treg immune subsets.

**Acknowledgements**

We would like to thank the staff of the Asia Clinical Laboratory in Najaf city for their help in the ELISA measurements. We greatly appreciate the continuous cooperation of the staff of the Psychiatry Unit at Al-Hakeem General Hospital.

**Funding**
There was no specific funding for this specific study.

Conflict of interest

The authors have no conflict of interest with any commercial or other association in connection with the submitted article.

Author’s contributions

All the contributing authors have participated in preparation of the manuscript.

References:

- Bay-Richter C, Linderholm KR, Lim CK, Samuelsson M, Träskman-Bendz L, Guillemin GJ, Erhardt S, Brundin L. A role for inflammatory metabolites as modulators of the glutamate N-


- Dahl J, Ormstad H, Aass HC, Malt UF, Bendz LT, Sandvik L, Brundin L, Andreassen OA. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology 2014;45, 77-86.


• Kolouri S, Firoozabadi A, Salehi A, Zarshenas MM, Dastgheib SA, Heydari M, Rezaeizadeh H. Nepeta menthoides Boiss. & and Buhse freeze-dried aqueous extract versus sertraline in


- Lee KM, Kim YK. The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. Int Immunopharmacol. 2006;6(8):1298-304.


• Maes M, Galecki P, Verkerk R, Rief W. Somatization, but not depression, is characterized by disorders in the tryptophan catabolite (TRYCAT) pathway, indicating increased indoleamine 2,3-dioxygenase and lowered kynurenine aminotransferase activity. Neuro Endocrinol Lett 2011c;32(3):264-73.


• Maes M, Verkerk R, Bonaccorso S, Ombelet W, Bosmans E, Scharpé S. Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation. Life Sci. 2002;71(16):1837-48.

• Maes M: Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and may even aggravate the pathophysiology underpinning depression. Metab Brain Dis. 2012a;27(4):405-13.

• Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R. The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011b;35(3):702-721.


• Maes M. Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression. Prog Neuropsychopharmacol Biol Psychiatry 2011a;35(3):664-75.


Table 1: Socio-demographic, clinical and biomarker data in healthy controls (HC) and major depressed (MDD) patients both before (baseline) and after (post-) treatment.

<table>
<thead>
<tr>
<th>Variables</th>
<th>HC²</th>
<th>MDD²</th>
<th>MDD³</th>
<th>F/χ²</th>
<th>df</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n=40</td>
<td>Baseline n=140</td>
<td>Post-treatment n=44</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>40.3(7.9)</td>
<td>39.0(10.6)</td>
<td>39.1(10.6)</td>
<td>0.27</td>
<td>2/221</td>
<td>0.764</td>
</tr>
<tr>
<td>Sex (F/M)</td>
<td>18/22</td>
<td>62/78</td>
<td>16/28</td>
<td>0.95</td>
<td>1</td>
<td>0.622</td>
</tr>
<tr>
<td>Smoking (Y/N)</td>
<td>4.00</td>
<td>82.58</td>
<td>31/13</td>
<td>24.78</td>
<td>2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Employment (Y/N)</td>
<td>18/22</td>
<td>81.59</td>
<td>24/20</td>
<td>2.08</td>
<td>2</td>
<td>0.353</td>
</tr>
<tr>
<td>Rural/Urban</td>
<td>29/11</td>
<td>67/73</td>
<td>16/28</td>
<td>6.00</td>
<td>2</td>
<td>0.050</td>
</tr>
<tr>
<td>Married/Single</td>
<td>22/18</td>
<td>51/89</td>
<td>7/37</td>
<td>14.03</td>
<td>2</td>
<td>0.001</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>27.7(4.2)</td>
<td>27.6(16.8)</td>
<td>26.4(4.7)</td>
<td>0.13</td>
<td>2/221</td>
<td>0.877</td>
</tr>
<tr>
<td>IDO (U/L)*</td>
<td>31.35(11.27)</td>
<td>41.11(18.28)</td>
<td>30.64(6.77)</td>
<td>9.59</td>
<td>2/221</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IFNγ (pg/ml)*</td>
<td>32.34(9.33)</td>
<td>46.18(17.68)</td>
<td>35.94(4.99)</td>
<td>17.35</td>
<td>2/221</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>IL-4 (pg/ml)*</td>
<td>198.29(51.49)</td>
<td>392.85(184.62)</td>
<td>219.39(59.36)</td>
<td>42.56</td>
<td>2/221</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>TGF-β1 (pg/ml)*</td>
<td>2102.4(589.9)</td>
<td>2875(1892.5)</td>
<td>1848.8(352.4)</td>
<td>19.12</td>
<td>2/221</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>zIL-4+zTGF-β1</td>
<td>-0.68(0.55)</td>
<td>-0.042(0.99)</td>
<td>-0.71(0.44)</td>
<td>46.23</td>
<td>2/221</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>zIFNγ-zIL-4-zTGF-β1</td>
<td>-0.03(0.88)</td>
<td>-0.15(1.12)</td>
<td>-0.44(0.37)</td>
<td>6.14</td>
<td>2/221</td>
<td>0.003</td>
</tr>
</tbody>
</table>

(*) Processed in Ln transformation

BMI: body mass index; IDO: indoleamine-2,3-dioxygenase; IFN: interferon; TGF: transforming growth factor-β1

zIL-4+zTGF-β1: computed as z transformation of interleukin (IL)-4 (z Ln IL-4) + z Ln TGF-β1;

zIFNγ-zIL-4+zTGF-β1: computed as z Ln IFNγ - z(z Ln IL-4 + z Ln TGF-β1)
Table 2. Results of multivariate GLM analysis with the biomarkers as dependent variables and diagnosis as explanatory variable while adjusting for extraneous variables.

<table>
<thead>
<tr>
<th>Tests</th>
<th>Dependent variables</th>
<th>Explanatory variables</th>
<th>F</th>
<th>df</th>
<th>p</th>
<th>Partial η²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multivariate</td>
<td>All biomarkers *</td>
<td>Diagnosis</td>
<td>14.92</td>
<td>4/171</td>
<td>&lt;0.001</td>
<td>0.259</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sex</td>
<td>0.37</td>
<td>4/171</td>
<td>0.833</td>
<td>0.008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Smoking</td>
<td>0.23</td>
<td>4/171</td>
<td>0.922</td>
<td>0.005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Age</td>
<td>0.94</td>
<td>4/171</td>
<td>0.441</td>
<td>0.022</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BMI</td>
<td>2.09</td>
<td>4/171</td>
<td>0.085</td>
<td>0.047</td>
</tr>
<tr>
<td>Between-subjects effects</td>
<td>IDO</td>
<td>Diagnosis</td>
<td>10.59</td>
<td>1/174</td>
<td>0.001</td>
<td>0.057</td>
</tr>
<tr>
<td></td>
<td>IFNγ</td>
<td>Diagnosis</td>
<td>24.27</td>
<td>1/174</td>
<td>&lt;0.001</td>
<td>0.122</td>
</tr>
<tr>
<td></td>
<td>IL-4</td>
<td>Diagnosis</td>
<td>44.46</td>
<td>1/174</td>
<td>&lt;0.001</td>
<td>0.203</td>
</tr>
<tr>
<td></td>
<td>TGF-β1</td>
<td>Diagnosis</td>
<td>11.37</td>
<td>1/174</td>
<td>0.001</td>
<td>0.061</td>
</tr>
<tr>
<td></td>
<td>IL-4+TGF-β1</td>
<td>Diagnosis</td>
<td>39.57</td>
<td>1/174</td>
<td>&lt;0.001</td>
<td>0.185</td>
</tr>
<tr>
<td></td>
<td>Th1/Th2+Treg</td>
<td>Diagnosis</td>
<td>0.94</td>
<td>1/174</td>
<td>0.333</td>
<td>0.005</td>
</tr>
</tbody>
</table>

Diagnosis: entered as major depression (baseline values only) versus healthy controls.

BMI: body mass index;

* All biomarkers were entered as dependent variables, namely IDO: indeoleamine-2,3-dioxygenase; IFN: interferon; IL-4: interleukin-4; TGF: transforming growth factor-β1 and two z unit weighted composite scores, zIL-4+zTGF-β1: computed as z transformation of Ln interleukin (IL)-4 (zIL-4) + z Ln TGF-β1, and Th1/Th2+Treg or zIFNγ-zIL-4+zTGF-β1 computed as z Ln IFN-γ – z(z Ln IL-4 + z Ln TGF-β1)
Table 3: Model-derived estimated marginal means of the biomarkers data (in z-values estimated after multivariate GLM analysis Table 2).

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>HC n=40</th>
<th>MDD n=140</th>
</tr>
</thead>
<tbody>
<tr>
<td>IDO</td>
<td>-0.495(0.175)</td>
<td>0.112(0.083)</td>
</tr>
<tr>
<td>IFN-γ</td>
<td>-0.720(0.171)</td>
<td>0.180(0.081)</td>
</tr>
<tr>
<td>IL-4</td>
<td>-0.883(0.160)</td>
<td>0.255(0.076)</td>
</tr>
<tr>
<td>TGF-β1</td>
<td>-0.510(0.177)</td>
<td>0.129(0.085)</td>
</tr>
<tr>
<td>Th2 + Treg</td>
<td>-0.859(0.163)</td>
<td>0.237(0.078)</td>
</tr>
<tr>
<td>Th1/Th2 + Treg</td>
<td>0.135(0.182)</td>
<td>0.055(0.087)</td>
</tr>
</tbody>
</table>

IDO: indoleamine 2,3-dioxygenase; IFN: interferon; IL-4: interleukin-4; TGF: transforming growth factor-β1 and two z unit weighted composite scores, Th2+Treg or zIL-4 + zTGF-β1: computed as z transformation of Ln interleukin (IL)-4 (zLn IL-4) + z Ln TGF-β1, and Th1/Th2+Treg or zIFN-γ·zIL-4 + zTGF-β1 computed as z Ln IFN-γ - z(z Ln IL-4 + z Ln TGF-β1)
Table 4: Socio-demographic, clinical, and biomarkers data of major depressed patients allocated to the ketoprofen-sertraline and placebo-sertraline treatment groups.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Sertraline n=16</th>
<th>Sertraline-ketoprofen n=28</th>
<th>F / X²</th>
<th>df</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>38.5(11.8)</td>
<td>39.4(10.1)</td>
<td>0.07</td>
<td>1/42</td>
<td>0.801</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>25.6(5.4)</td>
<td>26.9(4.3)</td>
<td>0.75</td>
<td>1/42</td>
<td>0.392</td>
</tr>
<tr>
<td>Sex (F/M)</td>
<td>6:10</td>
<td>10:18</td>
<td>0.01</td>
<td>1</td>
<td>0.906</td>
</tr>
<tr>
<td>Married / Single</td>
<td>3:13</td>
<td>4:24</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Rural / Urban</td>
<td>4:12</td>
<td>12:16</td>
<td>1.40</td>
<td>1</td>
<td>0.236</td>
</tr>
<tr>
<td>Employee (Y/N)</td>
<td>7:9</td>
<td>17:11</td>
<td>1.18</td>
<td>1</td>
<td>0.277</td>
</tr>
<tr>
<td>Smoking (Y/N)</td>
<td>10:6</td>
<td>21:7</td>
<td>0.76</td>
<td>1/42</td>
<td>0.382</td>
</tr>
<tr>
<td>BDI (Baseline)</td>
<td>49.9(8.3)</td>
<td>48.8(10.7)</td>
<td>0.13</td>
<td>1/42</td>
<td>0.720</td>
</tr>
<tr>
<td>IDO (U/L)*</td>
<td>37.73(13.83)</td>
<td>45.51(18.87)</td>
<td>2.88</td>
<td>1/42</td>
<td>0.097</td>
</tr>
<tr>
<td>IFNγ (pg/ml)*</td>
<td>49.91(17.19)</td>
<td>49.82(19.08)</td>
<td>0.01</td>
<td>1/42</td>
<td>0.907</td>
</tr>
<tr>
<td>IL-4 (pg/ml)*</td>
<td>511.68(199.70)</td>
<td>441.82(197.53)</td>
<td>1.25</td>
<td>1/42</td>
<td>0.271</td>
</tr>
<tr>
<td>TGF-β1 (pg/ml)*</td>
<td>3547.3(3410.9)</td>
<td>3513.7(2803.9)</td>
<td>0.55</td>
<td>1/42</td>
<td>0.465</td>
</tr>
</tbody>
</table>

(*): Processed in ln transformation

BMI: body mass index; IDO: indeoleamine-2,3-dioxygenase; IFN: interferon; IL-4: interleukin-4; TGF: transforming growth factor-β1
Table 5: Results of linear mixed model analyses (repeated measurements) performed on the biomarkers

<table>
<thead>
<tr>
<th></th>
<th>Time</th>
<th>Time x treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>t₀</td>
<td>t endpoint</td>
</tr>
<tr>
<td>BDI-II</td>
<td>49.38 (1.55)</td>
<td>16.56 (1.08)</td>
</tr>
<tr>
<td>IDO** (µL)*</td>
<td>44.8(4.8)</td>
<td>34.1(4.1)</td>
</tr>
<tr>
<td>IFNγ* (pg/ml)*</td>
<td>49.87(2.89)</td>
<td>39.49(0.73)</td>
</tr>
<tr>
<td>IL-4* (pg/ml)*</td>
<td>483.55(33.82)</td>
<td>233.44(15.67)</td>
</tr>
<tr>
<td>TGF-β1 (pg/ml)*</td>
<td>3537.0(479.0)</td>
<td>1896.7(64.4)</td>
</tr>
<tr>
<td>Th2+Treg</td>
<td>0.674(0.155)</td>
<td>-0.611(0.051)</td>
</tr>
<tr>
<td>Th1/Th2+Treg</td>
<td>-0.240(0.210)</td>
<td>0.228(0.060)</td>
</tr>
</tbody>
</table>

* All data were processed in Ln transformation

IDO: indoleamine-2,3-dioxygenase; IFN: interferon; IL-4: interleukin-4; TGF: transforming growth factor-β1 and two z unit weighted composite scores, Th2+Treg or zIL-4+zTGF-β1: computed as z transformation of Ln interleukin (IL)-4 (zIL-4) + z Ln TGF-β1, and Th1/Th2+Treg or zIFNγ·zIL-4·zTGF-β1 computed as z Ln IFN-γ - z(z Ln IL-4 + z Ln TGF-β1)